RxDoctor Payments Data

Robert Price, MD

Cardiovascular Disease · Matthews, NCNPI 1760480735

Payments from drug & device makers

$6,626in general payments, 2019–2025

Across 294 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novartis$1K
  • Abbott$482
  • Heartflow, Inc.$444
  • Amgen$413
  • Bayer$348
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,606100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,626 in reported general payments places this provider in the 65th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$141,697
Medicare patients
1,074
Services billed
2,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban658$643,989
XareltoRivaroxaban177$199,427
Repatha SureclickEvolocumab173$121,013
EntrestoSacubitril/Valsartan53$64,420
JardianceEmpagliflozin41$44,434
Praluent PenAlirocumab15$13,182
Ranolazine ErRanolazine60$9,049
Ezetimibe325$7,827
Metoprolol Succinate552$7,151
BrilintaTicagrelor13$5,799
Atorvastatin Calcium597$5,700
Flecainide Acetate154$5,020
Rosuvastatin Calcium397$3,639
Diltiazem 24hr Er (Cd)Diltiazem Hcl86$3,601
Nitroglycerin144$2,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$236$643,989658 claims
Johnson & JohnsonXarelto$1,521$199,427177 claims
NovartisEntresto$1,244$64,42053 claims
Boehringer IngelheimJardiance$188$44,43441 claims
AstraZenecaBrilinta$204$5,79913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →